이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Neurotech International 미래 성장

Future 기준 확인 2/6

Neurotech International (는) 각각 연간 25.1% 및 39.9% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 82.8% 만큼 쇠퇴할 것으로 예상됩니다. 자기자본이익률은 3년 후 -43% 로 예상됩니다.

주요 정보

33.6%

수익 성장률

-90.1%

EPS 성장률

Medical Equipment 수익 성장	16.7%
매출 성장률	44.7%
향후 자기자본 수익률	-45.0%
애널리스트 커버리지	Low
마지막 업데이트	16 Aug 2024

최근 미래 성장 업데이트

업데이트 없음

Recent updates

수익 및 매출 성장 예측

CHIA:NTI - 애널리스트의 미래 추정치 및 과거 재무 데이터 (AUD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
6/30/2027	3	-7	-8	-8	1
6/30/2026	3	-6	-6	-6	1
6/30/2025	2	-6	-6	-6	1
6/30/2024	3	-5	-5	-5	N/A
3/31/2024	3	-5	-4	-4	N/A
12/31/2023	3	-5	-4	-4	N/A
9/30/2023	2	-6	-5	-5	N/A
6/30/2023	1	-8	-6	-6	N/A
3/31/2023	1	-6	-5	-5	N/A
12/31/2022	2	-5	-4	-4	N/A
9/30/2022	1	-4	-4	-4	N/A
6/30/2022	1	-3	-3	-3	N/A
3/31/2022	0	-4	-3	-3	N/A
12/31/2021	0	-6	-3	-3	N/A
9/30/2021	0	-7	-3	-3	N/A
6/30/2021	0	-7	-2	-2	N/A
3/31/2021	0	-6	-2	-2	N/A
12/31/2020	0	-5	-1	-1	N/A
9/30/2020	0	-3	-1	-1	N/A
6/30/2020	0	-2	-1	-1	N/A
3/31/2020	0	-3	-1	-1	N/A
12/31/2019	0	-4	-1	-1	N/A
9/30/2019	0	-4	-2	-2	N/A
6/30/2019	0	-5	-3	-3	N/A
3/31/2019	0	-4	-3	-3	N/A
12/31/2018	0	-4	-4	-3	N/A
9/30/2018	0	-4	-4	-3	N/A
6/30/2018	0	-4	-4	-3	N/A
3/31/2018	0	-4	N/A	-3	N/A
12/31/2017	0	-4	N/A	-3	N/A
9/30/2017	0	-4	N/A	-3	N/A
6/30/2017	0	-4	N/A	-3	N/A
12/31/2016	0	-4	N/A	-3	N/A
9/30/2016	0	-4	N/A	-2	N/A
6/30/2016	0	-3	N/A	-2	N/A
12/31/2015	0	-1	N/A	-1	N/A

애널리스트 미래 성장 예측

수입 대 저축률: NTI 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: NTI 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: NTI 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: NTI 의 수익(연간 39.9% ) Australian 시장( 5.1% 보다 빠르게 성장할 것으로 예상됩니다. 5.1% 연간).

고성장 수익: NTI 의 수익(연간 39.9% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: NTI (는) 3년 내에 수익성이 없을 것으로 예상됩니다.

Neurotech International 미래 성장

Future 기준 확인 2/6

주요 정보

최근 미래 성장 업데이트

Recent updates

Full year 2024 earnings released: AU$0.006 loss per share (vs AU$0.01 loss in FY 2023)

Less than half of directors are independent

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Neurotech International Limited to Report Q1, 2024 Results on Oct 27, 2023

Neurotech International Limited, Annual General Meeting, Nov 15, 2023

Full year 2023 earnings released: AU$0.01 loss per share (vs AU$0.005 loss in FY 2022)

New minor risk - Financial data availability

Neurotech International Limited to Report Q4, 2023 Results on Jul 26, 2023

First half 2023 earnings released: AU$0.48 loss per share (vs AU$0.003 loss in 1H 2022)

Neurotech International Limited Announces First Patient Treated in Phase I/II PANDAS/PANS Trial

Neurotech International Limited Announces Approval for Additional Phase I/II ASD Trial Extension

Neurotech International Limited Receives HREC Approval for Phase I/II PANDAS/PANS Clinical Trial

Neurotech International Limited to Report Q3, 2023 Results on Jan 30, 2023

Neurotech International Limited Announces Grant of FDA Pre-IND Meeting for NTI164 in ASD

Neurotech International Limited Announces Passing of Professor Allan Cripps AO, Non-Executive Director

Neurotech International Limited Announces Commencement of Patient Randomisation and First Patient Successfully Treats Under New Phase II/III NTIASD2 Clinical Trial for Children with Autism Spectrum Disorder

Less than half of directors are independent

Neurotech International Limited, Annual General Meeting, Nov 30, 2022

Neurotech International Limited, Annual General Meeting, Nov 23, 2022

Neurotech International Limited Reports Further Significant Clinical Improvement at 20 Weeks for Paediatric Autism Patients Treated with NTI164

Neurotech International Limited Announces New Phase I/II Clinical Trial in Children with PANDAS/PANS

Neurotech International Limited Provides Autism Spectrum Disorder Phase I/II Clinical Trial Update

Less than half of directors are independent

Neurotech International Limited Announces Transition of Alexandra Andrews from Chief Executive Officer to a New Position of Chief Operating Officer

Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.015 loss in FY 2021)

Neurotech International Limited Announces Currently Finalising a Pivotal Phase II/III Clinical Trial Design to be Conducted in Australia

Neurotech International ORDINARY FULLY PAID to Be Deleted from OTC Equity

Neurotech International Limited Announces Executive Changes

Neurotech International Limited Announces Results with NTI164 in Paediatric ASD

High number of new directors

Neurotech International Limited Announces Important Developments Relating to the Study Protocol Assessing NTI164 in Children with Autism Spectrum Disorder

High number of new directors

Neurotech International Limited Announces Successful Developments Relating to Safety and Tolerability of NTI164 and Key Behavioural Parameters That Impact Autism Spectrum Disorder Patients

Neurotech International Limited Appoints Alexandra Andrews as Chief Executive Officer, Effective 8 March 2022

Neurotech International Limited Announces Nti164 Clinical Program Update

Full year 2021 earnings released: AU$0.015 loss per share (vs AU$0.011 loss in FY 2020)

Neurotech International Limited Announces the Continuation of Its Pre-Clinical Program in Neuro-Inflammatory Disease Models In-Line with Research and Development Pathway

Neurotech International Limited Initiates Phase I/II Open Label Study into Autism

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 2 million.

Neurotech International Limited Announces Strategic Cultivation Partnership with CannaPacific Limited

Neurotech International Limited Announces the Expansion of Its Exclusive License with Dolce Cann Global Pty Ltd

Neurotech International Limited Provides an Update on Clinical Study Program

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.

Neurotech International Limited Announces Initiation of Clinical Product Formulation Studies

Neurotech International Limited Announces Transition of Peter Griffiths as CEO

Neurotech International Limited Commences Landmark in Vitro Trials of Unique Cannabis Strains

Full year earnings released - AU$0.011 loss per share

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견